Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) released its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.70, Yahoo Finance reports. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million.

Day One Biopharmaceuticals Trading Down 5.8 %

Shares of DAWN opened at $14.31 on Thursday. The firm’s fifty day simple moving average is $14.00 and its two-hundred day simple moving average is $14.84. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $18.07. The stock has a market capitalization of $1.25 billion, a P/E ratio of -5.70 and a beta of -1.51.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Monday, April 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and raised their target price for the company from $11.00 to $24.00 in a report on Thursday. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Finally, Piper Sandler restated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $35.71.

Insider Activity

In other news, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total transaction of $320,200.00. Following the transaction, the insider now owns 1,121,081 shares in the company, valued at $17,948,506.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total value of $320,200.00. Following the transaction, the insider now owns 1,121,081 shares in the company, valued at $17,948,506.81. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Samuel C. Blackman sold 2,267 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the completion of the sale, the insider now owns 1,171,081 shares in the company, valued at $18,830,982.48. The disclosure for this sale can be found here. Insiders sold 73,300 shares of company stock worth $1,181,765 in the last quarter. 8.40% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.